Corbus Pharmaceuticals Holdings, Inc.

( )
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 7.40%149.710.0%$1204.54m
AMGNAmgen, Inc. 0.41%249.951.3%$706.86m
SNSSSunesis Pharmaceuticals, Inc. -3.38%8.000.7%$559.23m
NVAXNovavax, Inc. 10.82%194.6680.0%$539.68m
ILMNIllumina, Inc. 1.04%403.153.5%$527.32m
GILDGilead Sciences, Inc. 0.36%64.891.0%$472.42m
REGNRegeneron Pharmaceuticals, Inc. 0.90%477.042.7%$431.11m
VRTXVertex Pharmaceuticals, Inc. 1.10%215.941.9%$372.06m
ALXNAlexion Pharmaceuticals, Inc. -0.18%153.732.0%$315.33m
BIIBBiogen, Inc. 1.29%266.191.7%$292.97m
BNTXBioNTech SE 6.68%129.640.0%$218.80m
EXASEXACT Sciences Corp. 2.45%128.0018.4%$194.86m
NBIXNeurocrine Biosciences, Inc. 0.19%92.974.9%$172.50m
CRSPCRISPR Therapeutics AG 5.67%120.880.6%$169.35m
TXG10X Genomics, Inc. 4.81%197.360.0%$149.02m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.